psma617

Vipivotide tetraxetan (PSMA-617) is a highly potent inhibitor of prostate-specific membrane antigen (PSMA) with a Ki of 0.37 nM.

PSMA617-TCMC is a derivative of PSMA-617 with structure modification, in which the caroboxy groups in DOTA ring is replaced by TCMC macrocycle. PSMA-617 is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer.

Vipivotide tetraxetan Linker (PSMA-617 Linker) is a noncleavable peptide linker utilized in the synthesis of Vipivotide tetraxetan (PSMA-617), a ligand instrumental in producing 177Lu-PSMA-617. This radioactive molecule is applied in the treatment of prostate cancer[1].

EB-PSMA-617 is an advanced version of PSMA-617, designed to enhance pharmacokinetic properties through conjugation with Evans Blue (EB), thereby extending its circulation half-life for improved prostate tumor targeting and radiotherapy effectiveness. In preclinical studies with PC3-PIP-loaded mice, EB-PSMA-617 showed an extended blood half-life, greater accumulation in PSMA-positive tumors, and effective tumor elimination with reduced radioactivity.